Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, today announced it has entered right into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the usage of mid-infrared (mid-IR) technology within the bioprocessing market.
Through this agreement, Repligen will assume responsibility for the commercialization of Culpeo®, in addition to the event of future products and technologies in partnership with DRS Daylight Solutions (“Daylight”). Each firms will deal with expanding the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) based solutions and integrating these solutions into Repligen Chromatography and Filtration systems to expand the businesses’ presence within the fast-growing Process Analytics Technology (PAT) segment of the bioprocessing market.
Daylight’s patented QCL-IR technology measures higher order protein and nucleic acid structure, facilitating the measurement of protein aggregation, concentration and nucleic acid content and other critical attributes in biological manufacturing processes. Accurate readouts can be found in seconds, enabling real-time process monitoring in upstream and downstream manufacturing.
San Diego-based Daylight makes a speciality of the event and manufacturing of revolutionary solutions based on its QCL technology platform, which operates throughout the mid-IR spectral range. Daylight, known for best-in-class products supporting business, research, and aerospace and defense markets, entered the bioprocessing market in 2018 with its ground-breaking Culpeo® instrument.
We’re delighted to have signed this agreement with DRS Daylight Solutions, which complements our existing analytics portfolio from C Technologies, a pioneer in real-time, in-line process monitoring solutions. We imagine that the Daylight portfolio will serve to speed up and expand adoption of in-line process monitoring within the bioprocessing industry. We sit up for working with Tim Day and the team at Daylight.”
Tony J. Hunt, CEO, Repligen Corporation
Dr. Timothy Day, Senior Vice President and General Manager, DRS Daylight Solutions, said, “We’re very excited to partner with Repligen to make QCL-IR based solutions a game-changing technology in PAT. We imagine Repligen is the very best partner to perform this, given their success with C Technologies and their track record of innovation in bioprocessing. We sit up for working along with Tony Hunt and the Repligen team to supply bioprocessing customers this ground-breaking technology to measure critical process parameters in biologics manufacturing. With real-time and high reliability results, Culpeo® will ultimately improve production yields, reduce costs and ensure product quality.”